Pilot results of therapy of adult Ph-negative acute lymphoblastic leukemia according to the protocol of Research Group of Russian Hematological Centers ALL-2009

Pilot results of therapy of adult Ph-negative acute lymphoblastic leukemia according to the protocol of Research Group of Russian Hematological Centers ALL-2009

Aim. To review results of 2-year experience in execution of the protocol on the treatment of adult acute Ph-negative lymphoblastic leukemia ALL-2009. Material and methods. Of 111 patients registered in the study from November 2008 to December 2010 the analysis covered 96 patients from 23 hematologic...

Full description

Bibliographic Details
Main Authors: Elena Nikolaevna Parovichnikova, G A Klyasova, V G Isaev, A N Sokolov, A V Kokhno, V V Troitskaya, E V Mavrina, E E Khodunova, E N Ustinova, E O Gribanova, S K Kravchenko, V V Ryzhko, T S Kaporskaya, O Yu Baranova, S N Bondarenko, A S Nizametdinova, E V Kondakova, T V Ryl'tsova, A N Alufer'eva, O S Samoylova, O P Skamorina, L V Gavrilova, A S Pristupa, N A Vopilina, T S Konstantinova, I V Kryuchkova, L V Anchukova, T S Tikunova, K D Kaplanov, V A Lapin, V A Tumakov, M N Kozmina, S A Chernysh, E I Podol'tseva, S M Kulikov, Yu R Davidyan, V G Savchenko, E N Parovichnikova, T V Ryltsova, A N Aluferieva, O S Samoilova, E I Podoltseva
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2011-07-01
Series:Терапевтический архив
Subjects:
adult ph-negative acute lymphoblastic leukemia
sensitivity to prednisolone
l-asparaginasa
Online Access:https://ter-arkhiv.ru/0040-3660/article/view/30852
Description
Summary:Aim. To review results of 2-year experience in execution of the protocol on the treatment of adult acute Ph-negative lymphoblastic leukemia ALL-2009. Material and methods. Of 111 patients registered in the study from November 2008 to December 2010 the analysis covered 96 patients from 23 hematological centers in 18 towns of the RF. Results. Treatment according to the Protocol ALL-2009 resulted in achievement of a complete remission in 91.2% patients with low early lethality of 5.5%. Postremission lethality fell to 3.7% versus previous studies (22%). Overall 2-year survival and recurrence-free survival reached 77.6 and 78.4%, respectively. Detection of any chromosomic aberrations significantly affected recurrence-free survival: 74 vs 100% in patients with normal karyotype. Conclusion. Protocol All-2009 demonstrates high efficacy in moderate toxicity and good reproducibility in any hematologic center.
ISSN:0040-3660
2309-5342

Similar Items